Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03973489 · ClinicalTrials.gov registry record · Phase 4
Effects of Genotype on Resting State Connectivity During Methamphetamine Administration
A Phase 4 study, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- Phase 4
- Development phase
- 69
- Enrollment target
NCT03973489 is a Phase 4 study that has completed, run by Oregon Health and Science University. The registered enrollment target is 69 participants.
The verdict
NCT03973489, a Phase 4 study, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 69 participants
- Enrollment target
Study Summary
Addiction to methamphetamine (MA) is a serious health problem in the United States. Right now, there are no medically approved treatments for MA dependence. More research is needed to understand how MA affects the brain and to eventually develop medical interventions for MA addiction. The purpose of the study is to learn more about how MA use affects the brain by investigating a receptor in the brain called trace amine-associated receptor 1 (TAAR1). The investigators are hoping to find out if individuals with certain versions of the brain receptor react differently when given MA. The TAAR1 receptor has two prevalent genetic variations due to a single nucleotide polymorphism. These are the wild type (WT) and a common variant (CV). Preliminary studies have shown that these variants produce different connectivity (resting state functional connectivity or RSFC) in the brains of individuals with MA use disorder (MUD), specifically that individuals with the CV genotype exhibit lower RSFC than WT. In this study, MA will be administered to individuals with MA use disorder and healthy controls in order to: 1. Determine the influence of CV vs. WT genotype on RSFC and craving in individuals with chronic MUD and healthy controls. 2. Determine the effect of acute methamphetamine or placebo administration on the interaction of CV vs WT genotype on RSFC, craving, cognitive control, attention and subjective experience in MUD and healthy controls.
Interventions
- DRUG Placebo oral tablet
- BEHAVIORAL Magnetic resonance imaging (MRI)
- DRUG Methamphetamine Hydrochloride Tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2019-08-16 |
| Est. Completion | 2023-03-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03973489
The ClinicalTrials.gov registry entry for NCT03973489 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo oral tablet is the first listed.
NCT03973489 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03973489 about?
NCT03973489 is a clinical study titled "Effects of Genotype on Resting State Connectivity During Methamphetamine Administration". Addiction to methamphetamine (MA) is a serious health problem in the United States. Right now, there are no medically approved treatments for MA dependence. More research is needed to understand how MA affects the brain and to eventually develop medical interventions for MA addiction. The purpose of...
What is the current status of trial NCT03973489?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 69 participants. The study started on 2019-08-16. Estimated completion is 2023-03-31.
What interventions are being tested in trial NCT03973489?
The interventions under investigation include: Placebo oral tablet (DRUG), Magnetic resonance imaging (MRI) (BEHAVIORAL), Methamphetamine Hydrochloride Tablets (DRUG).
Who is sponsoring clinical trial NCT03973489?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.